LU86383A1 - Solutions a base de phenytoine,leur procede de preparation et leur application pharmaceutique - Google Patents

Solutions a base de phenytoine,leur procede de preparation et leur application pharmaceutique Download PDF

Info

Publication number
LU86383A1
LU86383A1 LU86383A LU86383A LU86383A1 LU 86383 A1 LU86383 A1 LU 86383A1 LU 86383 A LU86383 A LU 86383A LU 86383 A LU86383 A LU 86383A LU 86383 A1 LU86383 A1 LU 86383A1
Authority
LU
Luxembourg
Prior art keywords
sodium
solution
phenytotne
phenytoin
chollne
Prior art date
Application number
LU86383A
Other languages
English (en)
French (fr)
Inventor
Mahdi B Fawzi
Anne K Taylor
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of LU86383A1 publication Critical patent/LU86383A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LU86383A 1985-05-20 1986-04-01 Solutions a base de phenytoine,leur procede de preparation et leur application pharmaceutique LU86383A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73593285 1985-05-20
US06/735,932 US4642316A (en) 1985-05-20 1985-05-20 Parenteral phenytoin preparations

Publications (1)

Publication Number Publication Date
LU86383A1 true LU86383A1 (fr) 1986-09-02

Family

ID=24957819

Family Applications (1)

Application Number Title Priority Date Filing Date
LU86383A LU86383A1 (fr) 1985-05-20 1986-04-01 Solutions a base de phenytoine,leur procede de preparation et leur application pharmaceutique

Country Status (18)

Country Link
US (1) US4642316A (da)
JP (1) JPS61268618A (da)
AU (1) AU595790B2 (da)
BE (1) BE904476A (da)
CA (1) CA1268119A (da)
CH (1) CH668594A5 (da)
DE (1) DE3610330A1 (da)
DK (1) DK100786A (da)
ES (1) ES8707195A1 (da)
FR (1) FR2581871B1 (da)
GB (1) GB2175203B (da)
IT (1) IT1190282B (da)
LU (1) LU86383A1 (da)
NL (1) NL8600899A (da)
NZ (1) NZ215783A (da)
PH (1) PH22922A (da)
SE (1) SE8600998L (da)
ZA (1) ZA862094B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3828156A1 (de) * 1988-08-19 1990-02-22 Astrapin Pharmazeutische Praep Stabile waessrige loesung von fluorouracil
WO1999004798A1 (en) * 1997-07-22 1999-02-04 Warner-Lambert Company Lyophilized fosphenytoin sodium for parenteral use
US6245917B1 (en) 1998-03-20 2001-06-12 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
WO2004058152A2 (en) * 2002-12-16 2004-07-15 Ranbaxy Pharmaceuticals Inc. An extended release pharmaceutical composition of phenytoin sodium
EP2946810A1 (en) 2005-02-03 2015-11-25 TopoTarget UK Limited Combination therapy using an HDAC inhibitor and Vincristine for treating cancer
DE102005019393A1 (de) * 2005-04-25 2006-10-26 Basell Polyolefine Gmbh Polyethylenformmassen für Spritzgussanwendungen
AU2012213940B2 (en) * 2005-05-13 2015-03-26 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
CN102579417B (zh) * 2005-05-13 2014-11-26 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
EP2361619A1 (en) 2005-11-10 2011-08-31 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer
CA2632198C (en) * 2005-12-05 2013-10-01 Taro Pharmaceuticals North America, Inc. Pharmaceutical formulation containing phenytoin sodium and magnesium stearate
CA2700173C (en) * 2007-09-25 2016-10-11 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
WO2009109861A1 (en) * 2008-03-07 2009-09-11 Topotarget A/S Methods of treatment employing prolonged continuous infusion of belinostat
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
RU2559083C9 (ru) 2009-05-19 2016-01-20 Неуродерм Лтд Композиции для непрерывного введения ингибиторов допа-декарбоксилазы
CN110123743A (zh) 2010-11-15 2019-08-16 纽罗德姆有限公司 L-多巴、多巴脱羧酶抑制剂、儿茶酚-o-甲基转移酶抑制剂及其组合物的连续施用
WO2012082995A1 (en) 2010-12-15 2012-06-21 Nektar Therapeutics Oligomer-containing hydantoin compounds
WO2013183055A1 (en) 2012-06-05 2013-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
EP3116475B1 (en) 2014-03-13 2020-11-04 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
WO2023205615A1 (en) * 2022-04-18 2023-10-26 ISHA Therapeutics LLC Orally dissolving antimicrobial film compositions & methods of their use
US12109303B2 (en) 2022-04-18 2024-10-08 ISHA Therapeutics LLC Orally dissolving antimicrobial film compositions and methods of their use
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3749779A (en) * 1970-08-27 1973-07-31 American Home Prod Stable solutions of sodium diphenylhydantoin
JPS5221575B2 (da) * 1972-03-18 1977-06-11
US4260769A (en) * 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
US4163058A (en) * 1977-04-22 1979-07-31 Interx Research Corporation Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof

Also Published As

Publication number Publication date
IT1190282B (it) 1988-02-16
CH668594A5 (fr) 1989-01-13
AU5441286A (en) 1986-11-27
DE3610330A1 (de) 1986-11-20
CA1268119A (en) 1990-04-24
GB8607383D0 (en) 1986-04-30
PH22922A (en) 1989-01-24
ZA862094B (en) 1986-11-26
IT8647936A1 (it) 1987-10-24
SE8600998L (sv) 1986-11-21
FR2581871A1 (fr) 1986-11-21
IT8647936A0 (it) 1986-04-24
FR2581871B1 (fr) 1990-05-11
GB2175203A (en) 1986-11-26
DK100786D0 (da) 1986-03-05
BE904476A (fr) 1986-09-24
JPS61268618A (ja) 1986-11-28
NZ215783A (en) 1989-01-27
GB2175203B (en) 1988-09-14
NL8600899A (nl) 1986-12-16
ES555143A0 (es) 1987-07-16
US4642316A (en) 1987-02-10
AU595790B2 (en) 1990-04-12
ES8707195A1 (es) 1987-07-16
SE8600998D0 (sv) 1986-03-05
DK100786A (da) 1986-11-21

Similar Documents

Publication Publication Date Title
FR2581871A1 (fr) Solutions a base de phenytoine, leur procede de preparation et leur application pharmaceutique
CA2102778C (fr) Nouvelles compositions a base de derives de la classe des taxanes
EP0078785B1 (fr) Sels d'acide valproîque, leur préparation et leur utilisation
US4409233A (en) Highly concentrated preparations of dopa compounds
FR2584405A1 (fr) Sels de furosemide, composition pharmaceutique les contenant et leur procede de preparation
JP5297815B2 (ja) 医薬組成物
EP0835140B1 (fr) Complexes metalliques de polyaminoacides et leur utilisation en imagerie diagnostique
CA1281650C (en) Aqueous preparation containing cyclodextrin
JP5325779B2 (ja) 医薬組成物
EP0099799B1 (fr) Nouveaux sels d'amino- (et imino-) acides alpha, omega-sulfoniques N-substitués, vecteurs cationiques de haute pénétration cellulaire, procédé d'obtention
EP0244315A1 (fr) Procédé de préparation d'une solution pharmaceutique aqueuse d'un principe actif constitué par un acide organique
JP3917820B2 (ja) オザグレルナトリウム含有注射液およびその安定化方法
RU2313346C2 (ru) Фармацевтическая композиция
EP0092287B2 (fr) Sels d'acétylcystéine, leur préparation et leur utilisation
EP0920320A2 (fr) Composition pharmaceutique injectable contenant l'acide ursodesoxycholique ou l'acide tauroursodesoxycholique, une base forte et du trometamol
FR2690340A1 (fr) Nouveau procédé de stabilisation des préparations pharmaceutiques liquides et les compositions pharmaceutiques ainsi stabilisées en résultant.
RU2389491C2 (ru) Комплекс, содержащий меквитазин (mequitazine), циклодекстрин и агент взаимодействия
FR2535205A1 (fr) Solution pour injection a base de substances antirhumatismales et d'une cobalamine et procede pour sa preparation
JP2007106736A (ja) 注射用の医薬組成物
JP2003063963A (ja) オザグレルナトリウム含有注射液
JP2007191417A (ja) 医薬用の組成物
LU83081A1 (fr) Compositions antitumeurs
LU84421A1 (fr) Sels d'acide ursodesoxycholique,leur preparation et leur utilisation
BE887220A (fr) Compositions antitumeurs
KR20210073905A (ko) 이부프로펜 및 아르기닌을 함유하는 안정성이 개선된 주사용 제제